Elacestrant and exemestane for HR+/HER2- breast cancer that has spread
Part of Cancer, Skin clinical trials.
This trial tests combining elacestrant (a new hormone therapy) with exemestane (a standard hormone therapy) for people whose HR+/HER2- breast cancer has spread and who have already tried a CDK4/6 inhibitor with anastrozole or letrozole. It may help if your tumor shows certain activity on a special PET scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your breast cancer is hormone receptor-positive (HR+) and HER2-negative, and has spread or is locally advanced and cannot be removed by surgery or cured by radiation.
- You are a good candidate for hormone therapy (no emergency symptoms from the cancer).
- You have at least one tumor that can be measured or bone lesions that can be evaluated on imaging, and those tumors show high activity on a specific type of PET scan called FES-PET.
- You have already tried a CDK4/6 inhibitor (like palbociclib, ribociclib, or abemaciclib) together with anastrozole or letrozole for at least 12 months, and your cancer stopped responding or progressed during or within 28 days of finishing that treatment.
- You have not had any other treatment after that CDK4/6 inhibitor combination, and you are in generally good health (able to do daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.
This trial tests a new hormone therapy pill, elacestrant, for people with a specific type of breast cancer (ER+, HER2-) that has a certain genetic change (ESR1 mutation) and has grown despite previous hormone therapy. The goal is to see if this drug can help control the cancer.
This trial tests elacestrant, a new hormone therapy drug, in women whose advanced or spread breast cancer has stopped responding to first-line hormone treatment. The drug is designed to work against a specific genetic change (ESR1 mutation) that can develop in these cancers.
This trial tests a new hormone therapy pill (elacestrant) against standard hormone therapy for people with a common type of early breast cancer (ER+, HER2-) that has a higher chance of returning. You may qualify if you've already been on hormone therapy for 2 to 5 years and want to see if a different pill works better.
This trial tests a new combination of two targeted drugs (elacestrant and Enhertu) for people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultra-low) that did not respond to standard treatments like CDK4/6 inhibitors. The goal is to see if this combination works better than current options.
This trial tests a new hormone therapy pill, elacestrant, given alone or with another drug to suppress ovarian function before surgery. It's for premenopausal women with early-stage, hormone receptor-positive, HER2-negative breast cancer to see if it can shrink the tumor.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.